Nanlesta Pilgrim, PhD

ViiV Healthcare

Disclosure(s): GSK: Stocks/Bonds (Public Company); ViiV Healthcare: Employee

Poster(s):

• (P-1424) Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1879) Change in Healthcare Professional’s Identification, Counseling, and Adherence with Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings from the EBONI Study
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-1899) Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR)
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT